NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Restoring and Maintaining Bone in Osteopenic Female Rat SkeletonThis experiment contains the crucial data for the lose, restore, and maintain (LRM) concept, a practical approach for reversing existing osteoporosis. The LRM concept uses anabolic agents to restore bone mass and architecture (+ phase) and then switches to an agent with the established ability to maintain bone mass, to keep the new bone (+/- phase). The purpose of this study was to learn whether switching to an agent known chiefly for its ability to maintain existing bone mass preserves new bone induced by PGE2, in osteopenic,estrogen-depleted rats. The current study had three phases, the bone loss (-), restore (+), and maintain (+/-) phases. We ovariectomized (OX) or sham ovariectomized (sham-OX) 5.5 month-old female rats (- phase). The OX rats were treated 5 months postovariectomy with 1-6 mg PGE2, per kg/day for 75 days to restore lost cancellous bone mass (+ phase), and then PGE2, treatment was stopped and treatment began with 1 or 5 micro-g/kg of risedronate, a bisphosphonate, twice a week for 60 days (+/- phase). During the loss (-) phase, the cancellous bone volume of the proximal tibial metaphysis in the OX rat fell to 19% of initial and 30% of age-matched control levels. During the restore (+) phase, the cancellous bone volume in OX rats doubled. When PGE2 treatment was stopped, however, and no special maintenance efforts were made during the maintain (+/-) phase, the PGE2-induced cancellous bone disappeared. In contrast, the PGE2-induced cancellous bone persisted when the PGE2 treatment was followed by either a 1 or 5 micro-g treatment of risedronate per kg given twice a week for 60 days during the maintain (+/-) phase. The tibial shaft demonstrated very little cortical bone loss during the loss (-) phase in OX rats. The tibial shaft cortical bone fell some 8%. During the restore (+) phase, new cortical bone in OX rats increased by 22%. When PGE2 treatment was stopped and nothing was given during the maintain (+/-) phase, however, all but the PGE2-induced subperiosteal bone disappeared. In contrast, when PGE2 treatment was stopped and 1 micro-g risedronate per kg twice a week for 60 days was administered during the maintenance (+/-) phase, the PGE2-induced subperiosteal bone and some of the subendocortical bone and marrow trabeculae persisted. When 5 micro-g risedronate per kg was given twice a week, all the PGE2-induced bone persisted. The study shows that most of the new cancellous and cortical bone induced by PGE2, can be maintained for at least 60 days after discontinuing PGE2 by administering enough of the resorption inhibitor, risedronate. The lower dose of risedronate was not adequate to save most of the PGE2-induced endocortical bone.
Document ID
19970002974
Acquisition Source
Ames Research Center
Document Type
Reprint (Version printed in journal)
Authors
Tang, Li Ya
(Utah Univ. Salt Lake City, UT United States)
Jee, Webster S. S.
(Utah Univ. Salt Lake City, UT United States)
Ke, Hua Zhu
(Utah Univ. Salt Lake City, UT United States)
Kimmel, Donald B.
(Creighton Univ. Omaha, NE United States)
Date Acquired
August 17, 2013
Publication Date
January 1, 1992
Publication Information
Publication: Journal of Bone and Mineral Research
Volume: 7
Issue: 9
Subject Category
Life Sciences (General)
Report/Patent Number
NASA-CR-202472
NAS 1.26:202472
Accession Number
97N70168
Funding Number(s)
CONTRACT_GRANT: DE-FG02-89ER 60764 A 001
CONTRACT_GRANT: NAG2-435
CONTRACT_GRANT: AR-38346
CONTRACT_GRANT: DE-AC01-76EV 0019
Distribution Limits
Public
Copyright
Public Use Permitted.
Document Inquiry

Available Downloads

There are no available downloads for this record.
No Preview Available